Efficacy and safety of plasmapheresis without plasma transfusion tandem with chemotherapy to treat multiple myeloma
Efficacy and safety of plasmapheresis without plasma transfusion tandem with chemotherapy to treat multiple myeloma
复制标题
不输血浆血浆置换联合化疗治疗多发性骨髓瘤的疗效和安全性
DOI：
10.1080/16078454.2022.2140980
复制
发表时间：
2022-11
期刊：
影响因子：
1.9
通讯作者：
Zhangzhi Li
中科院分区：
文献类型：
--
作者：
Yigang Guo;Lulu Zhang;Rongyao Zhang;Meiling Zhou;Xu Chen;Chucheng Wan;Ping Hu;Yuanyuan He;Hua Jiang;Wei Geng;Weixing Zhang;Fariha Kanwal;Muhammad Fayyaz ur Rehman;Zhangzhi Li
【摘要】目的评价血浆置换不输血联合化疗治疗多发性骨髓瘤（MM）的疗效和安全性。方法回顾性研究72例新诊断的多发性骨髓瘤患者，分为两组；一组为化疗组（试验组），另一组为化疗组（对照组）。分别在血浆置换、初诊和4个化疗疗程后监测血浆球蛋白、β2-微球蛋白、肌酐、血管内皮生长因子（VEGF）和IL-6水平。分析各组化疗4个疗程后的总有效率，并记录不良事件。结果和讨论基线数据显示，67%的患者处于ISS III期，在试验组中表现出更严重的肾功能不全。两组患者初诊时血浆球蛋白、β2-微球蛋白、VEGF、IL-6水平差异有统计学意义。血浆置换3次后，血浆球蛋白、β2-微球蛋白、VEGF、IL-6明显降低。肌酐水平也有所降低，但差异无统计学意义。化疗4个疗程后，两组患者VEGF、IL-6水平均较初诊时显著降低；这些差异在统计学上是相当可观的。与对照组相比，试验组未发现不良事件。结论血浆置换可降低MM患者的球蛋白、β2-微球蛋白、血清VEGF和IL-6水平，改善肾功能，减轻部分患者的透析依赖。
ABSTRACT Objectives This study evaluates the efficacy and safety of plasmapheresis without plasma transfusion tandem with chemotherapy in treating multiple myeloma (MM). Method This retrospective study involves seventy-two patients, newly diagnosed with multiple myeloma, divided into two groups; one with plasmapheresis without plasma transfusion tandem with the chemotherapy group (Trial group), while the second was chemotherapy group (Control group). The levels of Plasma Globulin, β2-microglobulin, Creatinine, Vascular endothelial growth factor (VEGF), and IL-6 were monitored after plasmapheresis, at initial diagnosis, and after four chemotherapy courses. Overall response rate of groups after four courses of chemotherapy was analyzed, and the adverse events were recorded. Results and Discussion The baseline data showed that sixty-seven percent of patients were at the ISS III stage and showed more severe renal insufficiency in the Trial group. The Plasma Globulin, β2-microglobulin, VEGF and IL-6 levels were significantly different between the two groups during the initial diagnosis. After three times plasmapheresis, Plasma Globulin, β2-microglobulin, VEGF, and IL-6 were significantly reduced in the plasmapheresis group. The Creatinine levels were also lowered, but the differences were not statistically significant. After four courses of chemotherapy, the levels of VEGF and IL-6 in the two groups were significantly reduced than the initial diagnosis; the differences were statistically considerable. No adverse events were found in the trial group as compared to the control group. Conclusion Plasmapheresis reduces Globulin, β2-microglobulin, serum VEGF and IL-6 levels in MM, improves renal functions, and releases some patients from dialysis dependence.
登录
查看更多内容
影响因子：
1.7
作者：
Janique C Gill;D. Oakley;Oluwatoyosi A. Onwuemene
通讯作者：
Janique C Gill;D. Oakley;Oluwatoyosi A. Onwuemene
DOI：
--
发表时间：
2015
期刊：
Przeglad lekarski
影响因子：
--
作者：
J. Kaszuba-Zwoińska;Jerzy Gremba;Barbara Gałdzińska-Calik;K. Wójcik-Piotrowicz;P. Thor
通讯作者：
J. Kaszuba-Zwoińska;Jerzy Gremba;Barbara Gałdzińska-Calik;K. Wójcik-Piotrowicz;P. Thor
影响因子：
1.3
作者：
A. Rao;A. Reddy;C. Dinunno;Ibrahim Elali
通讯作者：
A. Rao;A. Reddy;C. Dinunno;Ibrahim Elali
影响因子：
24.7
作者：
Hutchison, Colin A.;Cockwell, Paul;Cook, Mark
通讯作者：
Cook, Mark
影响因子：
2.9
作者：
VJ Marder;J. Nusbacher;FW Anderson
通讯作者：
VJ Marder;J. Nusbacher;FW Anderson